Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO

RIGEL PHARMACEUTICALS INC

2024-Q1 EPS reported -$0.05 revenue$29,534,000

TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.
REZLIDHIA net sales $4.9M, up from $1.5M YoY, driven by increased demand.
Net loss improved to $8.2M ($0.05/sh) from $13.5M ($0.08/sh) in Q1 2023.
Acquired U.S. rights to GAVRETO (pralsetinib) for RET fusion-positive NSCLC/thyroid cancer; transition expected July 2024.
Cash and short-term investments $49.6M at March 31, 2024; credit facility amendment extended maturity by one year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RIGEL PHARMACEUTICALS INC reported first quarter ended March 31, 2024 results: revenue $29.5 million.

Period: first quarter ended March 31, 2024
Revenue: $29.5 million
Result: reported results

Exact text from the filing

2 tm2413689d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO ® , a

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-058017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.